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Pharmacokinetic studies with zinc(II)-phthalocyanine in tumour-bearing
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Summary Zn(II)-phthalocyanine (Zn-Pc) incorporated into unilamellar liposomes of dipalmitoyl-
phosphatidylcholine has been injected intraperitoneally (0.5mgkg-1) to BALB/c mice bearing a transplanted
MS-2 fibrosarcoma. The drug is specifically transported by serum lipoproteins and cleared from the serum via
the bile-gut pathway in a biphasic process: -60% of Zn-Pc is eliminated with a serum half-life of -9 hours,
while the remaining aliquot is eliminated at a very slow rate. Several normal tissues take up the drug within 3
hours after administration but release it almost completely after 24-48 hours. On the other hand, the tumour
shows a maximum concentration of Zn-Pc (-0.6.ugg-1 of tissue) after 18-24 hours; at this time, the ratio
between the Zn-Pc levels in the tumour and the muscle (which represents the surrounding normal tissue) is
-7.5. The results are discussed in terms of a possible use of Zn-Pc as a photosensitizer in the photodynamic
therapy of tumours.
Haematoporphyrin and haematoporphyrin derivative (HpD)
are presently used as sensitizers for the specific destruction
of tumours by photodynamic therapy (PDT) (Moan, 1986;
Spikes & Jori, 1987). Although the technique is being applied
for the treatment of a variety of neoplasias at both the
experimental and clinical level (Dougherty, 1984), PDT is
facing some problems and/or limitations. Thus, HpD as it is
prepared from Hp (Lipson et al., 1961) is a complex mixture
of porphyrins, whose composition is often not reproduced in
different preparations and may change as a function of
various experimental parameters (Bonnett et al., 1981;
Dougherty, 1983). So far, the most active components of
HpD, which have been reported to possess an ether
(Dougherty, 1985) or ester (Kessel, 1985) structure, have not
been isolated in a pure form. Moreover, PDT is usually
performed by irradiation with 620-630 nm light;
unfortunately, the molar absorptivity of Hp or HpD in this
wavelength range is very low (< 103 M-1 cm-1).
Phthalocyanines, which are structurally similar to
porphyrins, can potentially overcome some limitations of
PDT; in particular, they exhibit a strong absorption
(8-105M-1cm-1) in the 680-700nm region i.e., in
correspondence of light wavelengths endowed with a high
penetration power into biological tissues. The ability of
phthalocyanines and some of their metal derivatives to act as
efficient photosensitizers of simple biological substrates
(Spikes & Bommer, 1986) and cultured cells (Ben-Hur &
Rosenthal, 1985; Chan et al., 1986) has been documented.
Finally, Rousseau et al. (1985) have reported that tetra-
sulphophthalocyanines (TSPc) can accumulate in a
mammary adenocarcinoma in rats.
While tetrasulphophthalocyanines are suitable for in vivo
studies because of their high water-solubility, serious
problems may arise owing to the low degree of purity.
Actually, the presently adopted procedures for sulfonation of
phthalocyanines lead to mixtures of mono-, di-, tri- and
tetra-sulphonated compounds (Linstead & Weiss, 1950;
Moser & Thomas, 1983).
In general, underivatized phthalocyanines can be obtained
with a very high purity and display a good efficiency in the
generation of activated oxygen species (Maillard et al., 1980;
Wu et al., 1985). Such water-insoluble dyes can be
transported in the bloodstream via unilamellar liposomes
(Valduga et al., 1987); the latter carriers were shown to
induce an efficient targeting of experimental tumours by
water-insoluble porphyrins (Jori et al., 1983), possibly
through the preferential delivery of the incorporated drug to
serum lipoproteins (Jori, 1985). In this paper, we describe the
pharmacokinetic behaviour of liposome-bound Zn-




Zn2+-phthalocyanine (Zn-Pc) was supplied by Ciba-Geigy
(Switzerland) and used without further purification.
Sublimation of the sample under high vacuum showed a
degree of purity of 97% (Valduga et al., 1987). Dipalmitoyl-
phosphatidylcholine (DPPC), over 98% pure, was a product
of Sigma Chemical Co.; sodium dodecylsulphate (SDS) and
Sephacryl S-300 were purchased from Merck and Pharmacia,
respectively.
Animals and tumour
Female mice of the BALB/c strain (20-25 g body wt) were
obtained from Charles River (Como, Italy). The MS-2
fibrosarcoma was kindly supplied by Instituto Nazionale dei
Tumori, Milan. It was implanted in the right hind leg of the
mice by injection of 106 cells suspended in 0.1 ml of PBS.
The pharmacokinetic studies were begun at 8 days after
tumour implantation, when its diameter was in the 0.7-
1.0 cm range.
Pharmacokinetic studies
The Zn-Pc was injected- i.p. into tumour-bearing mice after
incorporation of the dye into small unilamellar liposomes of
DPPC following the procedure described by Valduga et al.
(1987): The Zn-Pc/DPPC ratio was 1:36 on a molar basis,
as assessed from the weighed amount of phospholipid
and absorbance measurements at 680 nm for Zn-Pc
(E= 1.68 x 105 M-1 cm- at 673nm). The injected dose of
Zn-Pc was 0.5mgkg- mouse body wt. At fixed times after
Zn-Pc administration the mice were sacrificed and several
tissues (tumour, muscle of the left hind leg, skin, liver,
spleen, kidneys, lungs) were removed, washed with PBS and
frozen until the analysis for Zn-Pc content was performed.
Blood samples were collected from the same mice, centri-
fuged at 3,000 rpm for 15min and the serum was analyzed
for Zn-Pc content. The elimination pathway of Zn-Pc was
studied by analysis of the faeces and urine collected from
healthy Wistar albino rats; which had been injected with
liposome-bound Zn-Pc at a dose of 0.5mgkg-1. Through-
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out the experiments the rats were maintained in metabolic
cages with free access to standard dietary chow and the
faeces and urines were collected until 48h after the adminis-
tration of Zn-Pc.
Recovery ofZn-Pcfrom tissue and serum specimens
Tissue samples (-200mg of wet wt) were homogenized in
4ml of 2% aqueous SDS as previously described (Jori et al.,
1983). The homogenate was magnetically stirred for 1 h at
room temperature. The suspension thus obtained was
centrifuged at 3,000rpm for 10min; the supernatant was
collected and its Zn-Pc content (ug drug ml-' solution) was
estimated by fluorescence measurements with a Perkin-Elmer
MPF4 apparatus. The results of Zn-Pc recovery were finally
referred to an identical weight of each tissue, i.e., 1 g. The
sample was placed in quartz cuvettes of 1 cm optical path
and its 600nm-excited fluorescence was recorded in the 630-
740nm spectral interval at a right angle to the incident light
beam; in this way, the contribution of scattered light could
be more easily subtracted. To minimize inner filter effects,
the absorbance of the analyzed solutions at the excitation
wavelength was kept below 0.1. The fluorescence intensity
data were converted into Zn-Pc concentration by
interpolation with a calibration plot built with known
amounts of Zn-Pc in 2% SDS; preliminary studies (Valduga
et al., 1987) have shown that under our experimental
conditions Zn-Pc is embedded in a monomeric state within
the surfactant micelles. In preliminary studies, the pellet
remaining after removal of the supernatant was resuspended
in 2% SDS (4ml) and processed as above described; only
negligible amounts of Zn-Pc fluorescence were observed.
Serum samples were diluted with suitable volumes of 2%
aqueous SDS, so that the absorbance at 600nm was lower
than 0.1. The fluorescence emission of Zn-Pc was then
determined as described above. The Zn-Pc fluorescence
obtained from tissue extracts was corrected for the
contribution of a 600nm-excitable background fluorescence
as observed in tissue extracts from control mice.
Chromatographic studies
Serum samples were chromatographed on a column
(1.7 x 140cm) of Sephacryl S-300, which had been
equilibrated with 0.01 M phosphate buffer at pH7.4,
containing 0.15M NaCl. The column was eluted at a flow-
rate of 26mlh- and 2.5ml-fractions were collected. The
fraction collector was connected to a 2238 LKB UV-cord
and the protein content was continuously recorded by
monitoring the absorbance of the eluate at 280nm. The
collected fractions were also analyzed for their Zn-Pc content
by measuring the intensity at 680nm of the 600nm-excited
fluorescence. This value was found to be proportional to the
integrated area of the whole fluorescence spectrum.
Results
The serum concentration of i.p.-injected Zn-Pc reaches a
maximum value at 3h after administration (Figure 1).
About 60% of Zn-Pc is eliminated with a half-life of -9 h,
whereas the serum levels of the remaining drug undergo an
approximately exponential decrease at a low rate. Closely
similar behaviour has been reported for HpD administered
to patients (Zalar et al., 1977). The rapid clearance of Zn-Pc
fro'm the serum appears to occur almost exclusively via the
bile-gut pathway. Actually, analyses of faeces eliminated
from Wistar rats which had been maintained in metabolic
cages for 48h after i.p. administration of the drug showed
the presence of a total amount of Zn-Pc ranging between 109
and 127jug as compared to a total recovery ranging between
0.66 and 0.81 jg of Zn-Pc from the urine collected over the
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Figure 1 Time-dependence of Zn-Pc concentration in the serum
of BALB/c mice bearing the MS-2 fibrosarcoma. The mice have






















Figure 2 Chromatogram of the serum of BALB/c mice 24h
after the administration of liposomal Zn-Pc at a dose of
0.5mgkg-'. The chromatogram show the absorbance at 280nm
(0-0) and the fluorescence emission at 680nm (0-0).
that at least 98% of the totally eliminated haematoporphyrin
from Wistar rats is recovered in the faeces.
Column chromatography of mouse serum on Sephacryl S-
300 allows us to separate three protein fractions (Figure 2).
Typically, at 24h after i.p.-administration to tumour-bearing
mice, the Zn-Pc fluorescence is specifically associated with
the second protein peak. This peak appears to be mainly
constituted by the lipoprotein class as determined by the
estimation of its cholesterol and phospholipid content (such
analyses were carried out as described by Jori et al., 1984).
The specific association of Zn-Pc with this group of serum
proteins is independent of the time after administration:
chromatographic patterns qualitatively identical with those
shown in Figure 2 were obtained for sera taken at various
times between 1 h and 1 week after administration of Zn-Pc.
The maximum concentration of Zn-Pc in the serum
corresponds with the maximum uptake of the drug by
several normal tissues, including liver, kidneys, spleen, lungs
and muscle (Figures 3 and 4). In Figure 4 we show
comparatively the time-dependency of Zn-Pc recovery from
the MS-2 fibrosarcoma and the muscle, i.e., the surrounding
normal tissue. All the recovery data represent the average of
the values obtained by separate analyses of the tissues taken
from groups of at least three animals for each time, the
largest deviation from the reported values being 20%.
Discussion
Some water-soluble metal complexes of TSPc have been
shown to be accumulated in significant amounts by brain
tumours implanted into mice (Frigerio, 1962) or other kinds
- aIa
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Figure 3 Uptake and release of Zn-Pc in lungs (0-0),
kidneys (U-U), liver (0-0) and spleen (Ai-A) of BALB/c
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Figure 4 Uptake and release of Zn-Pc in tumour ( -) and
muscle (0-0) of mice after injection of0.5mgkg- Zn-Pc.
of tumours in rats (see, for a recent review, Spikes, 1986).
The problem of the selectivity of TSPc uptake by tumour
tissues as compared with the tissue where the tumour growth
has been addressed by Tralau et al. (1987): their results,
although preliminary, would indicate a similar tumour-
specificity of TSPc in comparison with HpD.
The data presented in this paper show that the water-
insoluble Zn-Pc is also a good tumour-localizer, at least in
our animal model. In particular, maximal tumour
concentrations of Zn-Pc are found at -18-24h after i.p.
administration of the drug, while after this time period most
Zn-Pc has been released from normal tissues. Thus, at 24h,
the ratio of Zn-Pc content between the tumour and the
muscle, i.e., the surrounding normal tissue, is -7.5. One
should remember, however, that the muscle does not
represent the normal tissue where the MS-2 fibrosarcoma
originates or grows.
Several indications suggest that TSPc and Zn-Pc are
transported and delivered to tumours by at least partially
different mechanisms. Thus i.v. injected TSPc are rapidly (1-
3 h) accumulated by a fibrosarcoma implanted s.c. in the
flank and completely disappear from the serum within 3h
(Tralau et al., 1987). It is likely that the latter dyes are
mainly bound by serum albumin, as it has been observed for
tetrasulphonated porphyrins (Kessel, 1987; Milanesi et al.,
1987); albumin does not enter tumour cells, hence the
associated drug is present in the vascular stroma of the
neoplastic tissue at least for relatively short (24h) periods of
time after its administration. On the contrary, Zn-Pc is
specifically transported by lipoproteins: this fact is not
surprising in view of the highly lipophilic nature of the drug,
as well as the tendency of the liposome carriers of Zn-Pc
to fuse with the lipid matrix of lipoproteins and to release
the entrapped drug to lipoproteins (Mayhew &
Papahadjopoulos, 1983). Now, lipoproteins, especially LDL,
preferentially interact with neoplastic and endothelial cells of
tumour tissues through a receptor-mediated endocytosis, so
that the drug is delivered from inside the cells (Goldstein et
al., 1979; Netland et al., 1985). The high efficiency of Zn-Pc
binding by lipoproteins can thus be correlated with the high
amounts of drug accumulated by the tumour tissue
(-0.6pgg-1 tissue) in spite of the low injected doses, i.e.,
0.5mgkg-' body wt. The above considerations may explain
the different pharmacokinetic behaviour between Zn-Pc and
TSPc, although both types of phthalocyanines can act as
good tumour-localizing agents. Certainly, the control of such
a behaviour has a critical importance for achieving a
satisfactory degree of selectivity in the targeting of tumour
tissues by photosensitizing agents (Jori, 1985).
In this connection, Zn-Pc has the distinct advantage over
HpD and photofrin II of a more homogeneous distribution
among serum proteins. It has been shown that both
haematoporphyrin (Jori et al., 1984) and HpD (Kessel, 1987)
are transported by at least three different classes of serum
proteins; this fact may explain the heterogeneous and time-
dependent distribution of these porphyrins in tumour tissues
(Kessel, 1986).
On the other hand, detectable amounts of HpD and Zn-Pc
persist in the serum for some weeks after their
administration. This circumstance has been claimed (Zalar et
al., 1977) to be correlated with the prolonged skin photo-
sensitivity, which represents one major side effect of the
photodynamic therapy of tumours.
In order to obtain some information on this point, we
estimated the skin concentration of Zn-Pc in mice at selected
times. Although there was some degree of individual
variability of the recovery data, in no case was the skin
concentration of Zn-Pc between 1 h and 168h after
administration found to be >0.1 pugg- I tissue. Therefore,
one would not expect a significant level of skin photo-
sensitization by Zn-Pc. The relatively inefficient accumula-
tion of Zn-Pc by mouse skin may again be a consequence
of the mechanisms involved in the transport of this drug
in the bloodstream. We have observed that, upon in vitro
incubation of human serum with Zn-Pc incorporated into
DPPC liposomes, a selective association of the phthalo-
cyanine with lipoproteins takes place: at least 70% of the
drug is bound by HDL (Reddi et al., unpublished results).
HDL are known to be responsible for the prolonged serum
persistence of a major fraction of i.v. injected haemato-
porphyrin (Barel et al., 1986).
In summary, the present findings encourage us to test the
efficiency of liposome-carried Zn-Pc as a phototherapeutic
agent: although the actual clinical use of this drug requires
thorough toxicological studies. Experiments aimed at
assessing the optimal parameters for photodynamic therapy
of tumours with Zn-Pc are in progress in our laboratory.
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